Guidelines to compose an ideal bacteriophage cocktail

Methods in Molecular Biology

Volumn 1693, Issue , 2018, Pages 99-110

  Merabishvili, Maia ^a   Pirnay, Jean Paul ^a   De Vos, Daniel ^a  

^a QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

Author keywords

Adaptation of bacteriophages; Bacteria and bacteriophage of choice; Bacteriophage compatibility; Bacteriophage therapeutics; Host range; Virulent bacteriophages

Indexed keywords

BACTERIAL STRAIN; BACTERIOPHAGE; HOST RANGE; NONHUMAN; PHAGE THERAPY; PRACTICE GUIDELINE; BACTERIAL INFECTION; BACTERIUM; HUMAN; MICROBIOLOGY; PHYSIOLOGY; VIROLOGY;

BACTERIA; BACTERIAL INFECTIONS; BACTERIOPHAGES; GUIDELINES AS TOPIC; HUMANS;

EID: 85033678093     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-7395-8_9     Document Type: Chapter

References (51)

1. Verbeken G, Pirnay JP, Lavigne R et al (2014) Call for a dedicated European legal framework for bacteriophage therapy. Arch Immunol Ther Exp 62:117–129. https://doi.org/10.1007/s00005-014-0269-y
2. Verbeken G, Pirnay JP, Lavigne R et al (2016) Viruses that can cure, when antibiotics fail….J Microb Biochem Technol 8(1):021–024
3. Pelfrene E, Willebrand E, Cavaleiro Sanches A et al (2016) Bacteriophage therapy: a regulatory perspective. J Antimicrob Chemother 71:2071–2074. https://doi.org/10.1093/jac/dkw083
4. European Medicines Agency (2015) Workshop on the therapeutic use of bacteriophages, summary. http://wwwemaeuropaeu/docs/en_GB/document_library/Other/2015/07/WC500189409pdf. Accessed 23 Nov 2016
5. Debarbieux L, Pirnay JP, Verbeken G et al (2016) A bacteriophage journey at the European Medicines Agency. FEMS Microbiol Lett. https://doi.org/10.1093/femsle/ fnv225
6. Servick K (2016) Beleaguered phage therapy trial presses on drug development. Science 352 (6293):1506. https://doi.org/10.1126/sci ence.352.6293.1506
7. Kuhl S, Mazure H (2011) d’Hérelle. Preparation of therapeutic bacteriophages, appendix 1 from: Le Phénomène de la Guérison dans les maladies infectieuses: Masson et Cie, 1938, Paris—OCLC 5784382. Bacteriophage 1(2):55–65. https://doi.org/10.4161/bact.1.2.15680
8. Gill JJ, Hyman P (2010) Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol 11(1):2–14
9. Appelmans R (1921) Le dosage du bacteriophage. Compt Rend Soc Biol 85:1098
10. Buckling A, Brockhurst M (2012) Bacteria-virus coevolution. Adv Exp Med Biol 751:347–370. https://doi.org/10.1007/978-1-4614-3567-9_16
11. Ministry of Health of the USSR (1982) Guidelines for production of combined liquid pyo-bacteriophage preparation 242–82 (in Russian)
12. Ministry of Health of the USSR (1986) Guidelines for production of liquid staphylococcal phage preparation for injections 29–86 (in Russian)
13. Ministry of Health of the USSR (1987) Guidelines for production of typhoidal phage tablets with acid resistant covering 88 (in Russian)
14. Ministry of Health of the USSR (1980) Guidelines for production of liquid streptococcal phage preparation 167–80 (in Russian)
15. Merabishvili M, De Vos D, Verbeken G et al (2012) Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany. PLoS One. https://doi. org/10.1371/journal.pone.0052709
16. Adams MH (1959) Bacteriophages. Interscience Publishers, New York, NY
17. Galán JC, Tato M, Baquero MR et al (2004) Fosfomycin and rifampin disk diffusion tests for detection of Escherichia coli mutator strains. J Clin Microbiol 42:4310–4312
18. Oliveira H, Sillankorva S, Merabishvili M et al (2015) Unexploited opportunities for phage therapy. Front Pharmacol. https://doi.org/10.3389/fphar.2015.00180
19. Lobocka M, Hejnowicz M, Gagala U et al (2014) The first step to bacteriophage therapy: how to choose the correct phage. In: Borysowski J, Międzybrodzki R, Górski A (eds) Phage therapy. Current research and applications, 1st edn. Caister Academic Press, Norfolk
20. Carlson K (2005) Appendix: working with bacteriophages: common techniques and methodological approaches. In: Kutter E, Sulakvelidze A (eds) Bacteriophages. Biology and applications. CRC Press, Boca Raton, FL
21. Twest R, Kropinski A (2009) Bacteriophage enrichment from water and soil. Methods Mol Biol 501:15–21. https://doi.org/10.1007/978-1-60327-164-6_2
22. Weber-Dabrowska B, Jonczyk-Matysiak E, Zaczek M et al (2016) Bacteriophage procurement for therapeutic purposes. Front Microbiol 7:1813. https://doi.org/10.3389/fmicb. 2016.01813
23. Pirnay JP, Blasdel BG, Bretaudeau L et al (2015) Quality and safety requirements for sustainable phage therapy products. Pharm Res 32:2173–2179. https://doi.org/10.1007/s11095-014-1617-7
24. Alavidze Z, Aminov R, Betts A et al (2016) Silk route to the acceptance and re-implementation of bacteriophage therapy. Biotechnol J 11 (5):595–600. https://doi.org/10.1002/biot. 201600023
25. Abedon S (2011) Lysis from without. Bacteriophage 1(1):46–49. https://doi.org/10. 4161/bact.1.1.13980
26. Kutter E (2009) Phage host range and efficiency of plating. Methods Mol Biol 501:141–149. https://doi.org/10.1007/978-1-60327-164-6_14
27. D’Herelle F (1922) The bacteriophage: its role in immunity. Authorized translation by Smith G. Williams & Wilkins Company, Baltimore, MD
28. Friman VP, Soanes-Brown D, Sierocinski P et al (2015) Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates. J Evol Biol 29:188–198. https://doi. org/10.1111/jeb.12774
29. Sander M, Schmeiger H (2001) Method for host-idependent detection of generalized transducing bacteriophages in natural habitats. Appl Environ Microbiol 67:1490–1493
30. Waddell TE, Franklin K, Mazzocco A et al (2009) Methods Mol Biol 501:293–303. https://doi.org/10.1007/978-1-60327-164-6_25
31. Górski A, Międzybrodzki R, Borysowski J et al (2012) Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res 83:41–71. https://doi.org/10.1016/B978-0-12-394438-2.00002-5
32. De Paepe M, Leclerc M, Tinsley CR et al (2014) Bacteriophages: an underestimated role in human and animal health? Front Cell Infect Microbiol 4:39. https://doi.org/10. 3389/fcimb.2014.00039
33. Brockhurst MA, Buckling A, Rainey PB (2005) The effect of a bacteriophage on diversification of the opportunistic bacterial pathogen Pseudomonas aeruginosa. Proc R Soc Lond B 272:1385–1391
34. León M, Bastías R (2015) Virulence reduction in bacteriophage resistant bacteria. Front Microbiol 6:343. https://doi.org/10.3389/fmicb.2015.00343
35. Santander J, Robeson J (2007) Phage-resistance of Salmonella enteric serovar Enter-itidis and pathogenesis in Caenorhabditis ele-gans is mediated by the lipopolysaccharide. Electron J Biotechnol 10:627–632. https://doi.org/10.2225/vol10-issue4-fulltext-14
36. Capparelli R, Nocerino N, Lanzetta R et al (2010) Bacteriophage-resistant Staphylococcus aureus mutant confers broad immunity against staphylococcal infection in mice. PLoS One 5: e11720. https://doi.org/10.1371/journal. pone.0011720
37. Fish R, Kutter E, Wheat G et al (2016) Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care 7:S27–S33. 10.12968/jowc.2016.25.7.S27
38. Vandersteegen K, Mattheus W, Ceyssens PJ et al (2011) Microbiological and molecular assessment of bacteriophage ISP for the control of Staphylococcus aureus. PLoS One 6(9): e24418. https://doi.org/10.1371/journal. pone.0024418
39. Kvachadze L, Balarjishvili N, Meskhi T et al (2011) Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol 4(5):643–650. https://doi.org/10.1111/j. 1751-7915.2011.00259.x
40. Kaźmierczak Z, Górski A, Dąbrowska K (2014) Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool. Virus 6 (7):2551–2570. https://doi.org/10.3390/v6072551
41. Chanishvili N (2016) Bacteriophages as therapeutic and prophylactic means: summary of the Soviet and Post Soviet experiences. Curr Drug Deliv 13:309–323. https://doi.org/10.2174/156720181303160520193946
42. Abedon ST, Thomas-Abedon C (2010) Phage therapy pharmacology. Curr Pharm Biotechnol 11(1):28–47
43. Tanji Y, Shimada T, Yoichi M et al (2004) Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl Microbiol Biotechnol 64:270–274
44. Schmerer M, Molineux IJ, Bull JJ (2014) Synergy as a rationale for phage therapy using phage cocktails. Peer J 2:e590. https://doi. org/10.7717/peerj.590
45. Goodridge LD (2010) Designing phage therapeutics. Curr Pharm Biotechnol 11:15–27
46. Hall AR, De Vos D, Friman VP et al (2012) Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl Environ Microbiol 78:5646–5652. https://doi.org/10.1128/AEM.00757-12
47. Goodridge LD, Gallaccio A, Griffiths MW (2003) Morphological, host range, and genetic characterization of two coliphages. Appl Environ Microbiol 69:5364–5371
48. Scholl D, Rogers S, Adhya S et al (2001) Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J Virol 75(6):2509–2515
49. Sulakvelidze A, Kutter E (2005) Bacteriophage therapy in humans. In: Kutter E, Sulakvelidze A (eds) Bacteriophages. Biology and applications. Boca Raton, FL, CRC Press
50. Zschach H, Joensen KG, Lindhard B et al (2015) What can we learn from a metagenomic analysis of a Georgian bacteriophage cocktail? Virus 7(12):6570–6589. https://doi.org/10. 3390/v7122958
51. Chanishvili N (2012) A literature review of the practical application of bacteriophage research. Nova Science Publishers, Hauppauge, NY